Development of drug resistance to ALK-TKI leads to hyperactivation and development of secondary mutations in kinases such as EGFR, ERBB3, it is therefore worth exploring further the combination of ALK-TKI and ERRB inhibitors to overcome any emerge resistance of these tumours. This evidence concerns the gene ERBB3 and neoplasm.